SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

SPY003

SYRE·Spyre Therapeutics, Inc.
BULLISH
Drug Impact Rating5/10
Trial phase
Phase 2
Time to market
SPY003 is in Phase 2 with no regulatory filing yet. The next major readout (SKYLINE Part B combination induction data) is expected in 2027. Assuming positive Phase 2 and subsequent Phase 3 trials, potential approval would likely be several years away, likely 2029 or later.
Why 5/10
The next hard, dated catalyst is the SKYLINE Part B topline induction data for the pairwise combination regimens (SPY120, SPY130, SPY230), expected in 2027 (roughly 6-12 months from now). SPY003 is one of three components in Spyre's pipeline, but the combination strategy is central to the company's thesis. The impact score of 5 reflects a major program whose next binary catalyst is not precisely dated and is 6-12 months out, at a company with multiple programs and a strong cash runway.
Actionable Insight BULLISH

The next major catalyst is SKYLINE Part B combination data expected in 2027, which will test whether pairing SPY003 with SPY001 (anti-alpha4beta7) or SPY002 (anti-TL1A) produces meaningfully better efficacy than monotherapy. Positive combination data would be a major derisking event for the entire platform; negative or underwhelming results would raise questions about the combination strategy's value proposition in a competitive IL-23 market. The company's strong cash runway into H2 2029 removes near-term financing risk.

Price Chart

Loading chart...

Executive Summary

SPY003 is Spyre Therapeutics' extended half-life anti-IL-23 antibody for inflammatory bowel disease, currently in Phase 2 development. In September 2026, it met its primary endpoint in Part A of the SKYLINE trial for ulcerative colitis with a statistically significant 10-point RHI reduction (p<0.0001), completing proof-of-concept for all three of Spyre's IBD mechanisms. The drug's key differentiator is its ~85-day half-life, roughly triple that of marketed IL-23 inhibitors, potentially enabling quarterly or twice-yearly maintenance dosing. The stock trades near $99 with strong analyst support (mean PT $122.53) and a well-funded pipeline (~$1.47B cash). The next catalyst is the SKYLINE Part B combination data expected in 2027.

How It Works

SPY003 is an injectable monoclonal antibody that blocks IL-23, a protein that drives chronic inflammation in the gut. It is engineered with a YTE modification that makes it last much longer in the body (about 85 days half-life vs roughly 28 days for existing IL-23 blockers), which could allow patients to receive injections once every 3 to 6 months instead of every 4 to 8 weeks.

Trial Status

SPY003 completed Part A of the Phase 2 SKYLINE platform trial in ulcerative colitis (UC), reporting positive 12-week induction topline data on September 8, 2026. The trial met its primary endpoint with a statistically significant 10.0-point reduction in Robart's Histopathology Index (RHI) score (p<0.0001). Secondary endpoints showed 20% clinical remission by modified Mayo Score and 30% endoscopic improvement. Safety was consistent with the IL-23 class. Part B of SKYLINE, which evaluates pairwise combinations of SPY003 with SPY001 (anti-alpha4beta7) and SPY002 (anti-TL1A), is enrolling ahead of schedule.

The Two-Sided Case

▲ Bull Case5
SPY003 met its Phase 2 Part A primary endpoint with high statistical significance (10.0-point RHI reduction, p<0.0001), achieving proof-of-concept for all three IBD mechanisms in Spyre's portfolio.
SPY003's ~85-day half-life is roughly 3x longer than risankizumab (Skyrizi), supporting potential quarterly or twice-yearly maintenance dosing, a significant convenience advantage over current standard-of-care IL-23 inhibitors.
The company has a very strong cash position of approximately $1.47 billion pro forma (as of September 30, 2026), providing runway into the second half of 2029 and fully funding the pipeline through multiple catalysts.
Analyst consensus is strongly bullish: 21 Buy/Strong Buy ratings vs 2 Hold, with a mean price target of $122.53 (23.4% upside from $99.27) as of November 4, 2026.
Major institutional investors added or doubled positions in Q2 2026, including Price T Rowe Associates (+85%), Vanguard (+298%), Capital World Investors (+247%), and Goldman Sachs (+448%).
▼ Bear Case5
IL-23 inhibitors are a crowded, commercially established class with AbbVie's Skyrizi (risankizumab) generating over $9 billion in 2024 revenue and J&J's Tremfya (guselkumab) and Lilly's mirikizumab already approved, making market entry challenging.
SPY003's Phase 2 Part A efficacy signals (20% clinical remission, 30% endoscopic improvement at 12 weeks) are in line with the IL-23 class but not clearly superior to approved drugs, raising questions about differentiation beyond dosing convenience.
Insider selling was heavy in September-October 2026: CEO Cameron Turtle and other executives sold multimillion-dollar blocks under 10b5-1 plans, which may signal limited near-term upside conviction.
Elevated short-sale volume (66.2% of off-exchange volume on November 4, 2026, with a z-score of 1.72 vs the stock's own history) indicates significant bearish positioning.
Q3 2026 earnings missed consensus (EPS of -$0.94 vs -$0.785 estimate), and the net loss widened to $96.1 million from $11.2 million a year earlier as pipeline spending accelerated.

Upcoming Catalysts

  • SKYLINE Part B topline induction data for pairwise combinations (SPY120, SPY130, SPY230) expected in 2027
  • Potential initiation of Phase 3 program for SPY003 or combinations after Part B data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report

Sources · 11

Hover a chip for the title
1 spyre.com2 ir.spyre.com3 biospace.com4 sec.gov5 marketscreener.com6 panabee.com7 academic.oup.com8 timothysykes.com9 hcplive.com10 fiercebiotech.com11 marketbeat.com